

"Express Mail" mailing label number EL990716326US

Date of Deposit March 31, 2004

I hereby certify that this correspondence is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 CFR 1.10 on the date indicated above and is addressed to Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313-1450.

Laura L. Frieko 52,920
Attorney/Agent mailing application Registration No.

Laura L. Frieko
Signature of Attorney/Agent mailing application

P&G Case 8482D

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In the application of :
D. L. BISSETT ET AL. : Confirmation No.
Serial No. : Group Art Unit 1617
Filed : Examiner

For Skin Care Compositions Containing a Sugar Amine

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents
P. O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

Pursuant to 37 C.F.R. §§ 1.56, 1.97 and 1.98, record is being made on the attached Form PTO/SB08 of documents which the Patent Office may wish to consider in connection with examination of the above-identified patent application. It is respectfully requested that the cited documents be carefully considered by the Examiner and made of record in this case. As provided in §1.97(g), no representation is made or intended that a thorough art search was made. As provided in 37 C.F.R. §1.97(h), this Information Disclosure Statement does not constitute an admission of any kind, and specifically is not an admission that the documents listed on attached form PTO/SB08 are, or are considered to be, material to the patentability of the above-identified patent application, as defined in 37 C.F.R. §1.56(b).

1. 37 C.F.R. §1.97(b)(1) - U.S. Direct (use when filing IDS with nonprovisional patent application, or with Request for Continued Examination (RCE); or within 3 months of filing a nonprovisional patent application)

This information disclosure statement, submitted under 37 C.F.R. §1.97(b)(1), is being filed with the patent application, with a Request for Continued Examination or within three months of the filing date of a national application. Therefore, no fee is believed to be due.

2. **37 C.F.R. §1.97(b)(3)** - (use when filing IDS more than 3 months after filing a nonprovisional patent application, but prior to receipt of first Office Action)

This information disclosure statement is being submitted under 37 C.F.R. §1.97(b)(3). Applicants have not received an Office Action on the merits in the present application. Therefore, no fee is believed to be due. However, in the event that this paper is crossing in the mail with a first Office Action on the merits, authorization is hereby given to charge the required fee pursuant to 37 C.F.R. §1.97(c) and 37 C.F.R. §1.17(p) to Deposit Account No. 16-2480 in the name of The Procter & Gamble Company. A duplicate of this letter (or a fee transmittal form) is enclosed to facilitate charging of the fee, if necessary.

3. **37 C.F.R. §1.97(b)(4)** - (use when filing IDS prior to receipt of first Office Action after the filing of a Request for Continued Examination (RCE) under §1.114)

This information disclosure statement is being submitted under 37 C.F.R. §1.97(b)(4). Applicants have not received a first Office Action after filing a Request For Continued Examination (RCE). Therefore, no fee is believed to be due. However, in the event that this paper is crossing in the mail with a first Office Action on the merits, authorization is hereby given to charge the required fee pursuant to 37 C.F.R. §1.97(c) and 37 C.F.R. §1.17(p) to Deposit Account No. 16-2480 in the name of The Procter & Gamble Company. A duplicate of this letter (or a fee transmittal form) is enclosed to facilitate charging of the fee, if necessary.

4. **37 C.F.R. §1.97(c) with fee payment** - (use when filing IDS after receipt of first Office Action, and before receipt of Final Office Action, Notice of Allowance, or an action that otherwise closes prosecution)

This information disclosure statement is being submitted under 37 C.F.R. §1.97(c). Applicant(s) have not received a final action under 37 C.F.R. §1.113, a notice of allowance under 37 C.F.R. §1.311, or an action that otherwise closes prosecution in the application (e.g., *Ex parte Quayle*) as of the date of this submission. Applicant(s) elect to pay the fee set forth in 37 C.F.R. §1.17(p). Please charge the fee set forth in 37 C.F.R. §1.17(p) to Deposit Account Number 16-2480 in the name of The Procter & Gamble Company. A duplicate copy of this letter (or a fee transmittal form) is enclosed to facilitate the charging of the fee.

5. **Information to be Considered with Continued Prosecution Application (CPA) Filing (use when filing IDS with a Continued Prosecution Application (CPA) for Design Case)**. This information disclosure statement is being filed with a Continued Prosecution Application (CPA) filed under 37 C.F.R. 1.53(d).

ADDITIONAL ITEMS TO BE NOTED BY THE EXAMINER:

(1) (For use with applications filed after June 30, 2003.) In accordance with 37 C.F.R. §1.98(a)(2), Applicants are submitting copies of foreign patent documents and non-patent literature.

OR

(2) All of the cited references were previously cited by or submitted to the USPTO in prior application Case No. 8482, U.S. Patent Application Serial No. 10/097716, filed March 13, 2002. Applicants claim priority to said application under 35 U.S.C. §120. Accordingly, copies of previously submitted references are not provided with this Statement, pursuant to 37 C.F.R. §1.98(d). It is respectfully requested that the cited documents be carefully considered by the Examiner and made of record in this case.

OR

(3) Copies of all said documents, except Cite Numbers _____, were submitted and considered in parent application U.S. Patent Application Serial No. _____, filed _____. Applicant(s) claim priority to said application under 35 U.S.C. §120. Accordingly, copies of previously submitted references are not provided with this Statement, pursuant to 37 C.F.R. §1.98(d). Copies of references not previously submitted are enclosed. It is respectfully requested that the cited documents be carefully considered by the Examiner and made of record in this case.

(4) Pursuant to 37 C.F.R. §1.98(c), a concise explanation of the relevance of each cited reference that is not in the English language is provided.

(5) Applicants also respectfully request the Examiner to consider and make of record the co-pending applications listed on the attached page.

Additional information is attached.

Respectfully submitted,

By Laura L. Frieko

Laura L. Frieko
Registered Patent Agent
Registration No. 52,920
(513) 626-2721

March 31, 2004

Customer No. 27752

Please type a plus sign (+) inside this box → [+]

PTO/SB08A (10-01)

Approved for use through 10/31/2002 OMB 0651-0031

Patent and Trademark Office; U. S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO

COMPLETE IF KNOWN

Application Number	
Confirmation Number	
Filing Date	03/31/2004
First Named Inventor	Donald Lynn Bissett
Group Art Unit	1617
Examiner Name	
Attorney Docket Number	8482D

SHEET 1 of 3

U. S. PATENT DOCUMENTS

EXAMINER INITIALS*	Cite No. ¹	DOCUMENT NUMBER Number - Kind Code ² (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines Where Relevant Passages or Relevant Figures Appear
01	US-3,859,436 A	01/07/1975	Jacobi		
02	US-4,473,551 A	09/25/1984	Schinitzky		
03	US-4,772,591 A	09/20/1988	Meisner		
04	US-4,990,330 A	02/05/1991	Oyama		
05	US-5,141,964 A	08/25/1992	Noel		
06	US-5,215,759 A	06/01/1993	Mausner		
07	US-5,217,962 A	06/08/1993	Burton et al.		
08	US-5,254,331 A	10/19/1993	Mausner		
09	US-5,364,845 A	11/15/1994	Henderson		
10	US-5,391,373 A	02/21/1995	Mausner		
11	US-5,587,363 A	12/24/1996	Henderson		
12	US-5,639,740 A	06/17/1997	Crandall		
13	US-5,733,572 A	03/31/1998	ImaRx Pharm.		
14	US-5,795,573 A	08/18/1998	Paradise		
15	US-5,804,594 A	09/08/1998	Murad		
16	US-5,866,142 A	02/02/1999	Riordan		
17	US-5,874,463 A	02/23/1999	Ancira		
18	US-5,877,212 A	03/02/1999	Yu et al.		
19	US-5,908,867 A	06/01/1999	Henry et al.		
20	US-5,917,088 A	06/29/1999	Philippe et al.	= WO 97/12597A	
21	US-5,945,409 A	09/21/1999	Crandall		
22	US-5,955,083 A	09/28/1999	Bonte et al.	= WO 97/06659A	
23	US-5,972,999 A	10/26/1999	Murad		
24	US-6,110,966 A	08/29/2000	Pollock		
25	US-6,159,485 A	12/12/2000	Yu et al.		
26	US-6,358,539 B1	03/19/2002	Murad		
27	US-6,391,863 B1	05/21/2002	Philippe et al.	= WO 97/12597A	
28	US-2002/086070 A1	07/04/2002	Kuhrt		
29	US-2002/098253 A1	07/25/2002	Riley		

FOREIGN PATENT DOCUMENTS

EXAMINER INITIALS*	Cite No. ¹	FOREIGN PATENT DOCUMENT Country Code ³ Number ⁴ Kind Code ⁵ (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines Where Relevant Passages or Relevant Figures Appear	T ⁶
30	CH 458627 A	01/1968	Kolm Lab			Abstract
31	DE 19858811 A	06/29/2000	Cognis Deut GmbH			Abstract
32	DE 19858819 A	06/29/2000	Cognis Deut GmbH			Abstract
33	EP 0281812 A1	09/14/1988	Milor Sci. Ltd.			
34	EP 0295092 B1	12/14/1988	Unilever PLC			
35	EP 0312700 A2	04/26/1989	Curti			
36	EP 0414608 B1	02/24/1991	Roussel-UCLAF			
37	EP 0565785 A1	10/20/1993	LeVeen			
38	EP 0852946 A2	07/15/1998	De Paoli Ambrosi			
39	EP 0985408 A2	03/15/2000	Beiersdorf			Abstract
40	EP 1038516 A1	09/27/2000	Uchikuga			
41	EP 1075836 A2	02/14/2001	Y. Suisankagaku Industry			
42	FR 2609397 A1	07/15/1988	Serobiologiques Lab SA			Abstract

Please type a plus sign (+) inside this box → [+]

PTO/SB08A (10-01)

Approved for use through 10/31/2002 OMB 0651-0031

Patent and Trademark Office; U. S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

COMPLETE IF KNOWN

Application Number	
Confirmation Number	
Filing Date	03/31/2004
First Named Inventor	Donald Lynn Bissett
Group Art Unit	1617
Examiner Name	
Attorney Docket Number	8482D

SHEET 2 of 3

FOREIGN PATENT DOCUMENTS - continued

EXAMINER INITIALS*	Cite No. ¹	FOREIGN PATENT DOCUMENT	Country Code ³ Number ⁴ Kind Code ⁵ (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines Where Relevant Passages or Relevant Figures Appear	T ⁶
	43	FR 2732215 B		10/04/1996	Sederma		Claims only
	44	FR 2723316 B		02/09/1996	Thorel		Abstract
	45	GB 2265086 B		09/22/1993	Pacific Chem. Co. Ltd.		Abstract
	46	GB 2273044 B		06/08/1994	Pacific Chem. Co. Ltd.		Abstract
	47	JP 59013708 A		01/24/1984	Shiseido		Abstract
	48	JP 59039813 A		03/05/1984	Shiseido		Abstract
	49	JP 59039814 A		03/05/1984	Shiseido		Abstract
	50	JP 61238712 A		10/24/1986	Shiseido		Abstract
	51	JP 63119844 A		05/24/1988	Shiseido		Abstract
	52	JP 64-083011		03/28/1989	Sansho Seiyaku K.K.	X	
	53	JP 01117815 A		05/10/1989	Pola		Abstract
	54	JP 01186811 A		07/26/1989	Sunstar	X	
	55	JP 02078604 A		03/19/1990	Ucgunny Ogarcis		Abstract
	56	JP 02273608 A		11/08/1990	Taiyo Kaaku	X	
	57	JP 04009315 A		01/14/1992	Sunstar		Abstract
	58	JP 04029915 A2		01/31/1992	Sunstar		
	59	JP 04036210 A		02/06/1992	Daiichi Kasei		Abstract
	60	JP 04054126 A		02/21/1992	Mori		Abstract
	61	JP 04198196 A		07/17/1992	Kowa		Abstract
	62	JP 2916948 A		07/17/1992	Kowa Co. Ltd.		Abstract
	63	JP 05186324 A		07/27/1993	Sunstar	X	
	64	JP 07258060 A		09/22/1993	Pacific Chem. Co. Ltd.		Abstract
	65	JP 07206632 A		08/08/1995	Shiseido		Abstract
	66	JP 07233038 A		09/05/1995	Shiseido		Abstract
	67	JP 07233041 A		09/05/1995	Shiseido		Abstract
	68	JP 08133956 A		05/28/1996	Shiseido		Abstract
	69	JP 08133957 A		05/28/1996	Shiseido		Abstract
	70	JP 08133958 A		05/28/1996	Shiseido		Abstract
	71	JP 08231343 A		09/10/1996	Seiyaku		Abstract
	72	JP 08231347 A		09/10/1996	Seiyaku		Abstract
	73	JP 08268868 A		10/15/1996	Shiseido		Abstract
	74	JP 09077634 A		03/25/1997	Seiyaku		Abstract
	75	JP 09241124 A		09/16/1997	Shiseido		Abstract
	76	JP 10279459 A		10/20/1998	Mossjom Po; <0;>s		Abstract
	77	JP 10279485 A		10/20/1998	Nisshin Oil Mills		Abstract
	78	JP 11092326 A		04/06/1999	Shiseido		Abstract
	79	JP 11180853 A		07/06/1999	Shiseido		Abstract
	80	JP 11246339 A		09/14/1999	Shiseido		Abstract
	81	JP 11269035 A		10/05/1999	Shiseido		Abstract
	82	JP 2000026270 A2		01/25/2000	Isehan KK		Abstract
	83	JP 2000050842 A		02/22/2000	Fanchel		Claims only
	84	JP 2000139408 A		05/23/2000	Yaidzu Suisan Kagaku Kogyo Co.	X	
	85	JP 2000248276 A		09/12/2000	Yaidzu Suisan Kagaku Kogyo Co		Abstract
	86	JP 2001002551 A		01/09/2001	Kanebo		Abstract
	87	JP 2002114668 A		04/16/2002	Noevir		Abstract

Please type a plus sign (+) inside this box → [+]

PTO/SB08A (10-01)

Approved for use through 10/31/2002 OMB 0651-0031
Patent and Trademark Office; U. S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO

COMPLETE IF KNOWN

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

SHEET 3 of 3

Application Number

Confirmation Number

Filing Date

03/31/2004

First Named Inventor

Donald Lynn Bissett

Group Art Unit

1617

Examiner Name

Attorney Docket Number

8482D

FOREIGN PATENT DOCUMENTS - continued

EXAMINER INITIALS*	Cite No. ¹	FOREIGN PATENT DOCUMENT		Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines Where Relevant Passages or Relevant Figures Appear	T ⁶
		Country Code ³	Number ⁴				
	88	WO	87/02244 A1	04/03/1987	Hendry		
	89	WO	94/22453 A1	10/13/1994	Nutramax Lab		
	90	WO	97/17977 A1	05/22/1997	Everest-Todd Research		
	91	WO	98/03149 A1	01/29/1998	Handelman		
	92	WO	98/27988 A1	07/02/1998	Nutramax Lab		
	93	WO	98/42309 A1	10/01/1998	Crandall		
	94	WO	98/42348 A1	10/01/1998	Crandall		
	95	WO	98/46217 A1	03/02/1999	Van Scott et al. et al.		
	96	WO	98/48816 A1	11/50/1998	Nutramax Lab		
	97	WO	98/52576 A1	11/26/1998	New Key Foods		
	98	WO	99/24011 A1	05/20/1999	Murad		
	99	WO	99/62524 A1	12/09/1999	Nutramax Lab		
	100	WO	99/63950 A1	12/16/1999	Shiseido		Abstract
	101	WO	00/40217 A1	07/13/2000	Yugenic Ltd Partnership		
	102	WO	00/47169 A1	08/17/2000	Procter & Gamble		
	103	WO	00/47170 A1	08/17/2000	Procter & Gamble		
	104	WO	00/47171 A1	08/17/2000	Procter & Gamble		
	105	WO	00/47182 A1	08/17/2000	Procter & Gamble		
	106	WO	00/56327 A1	09/28/2000	Bioderm		
	107	WO	00/67722 A1	11/16/2000	Color Access Inc.		
	108	WO	01/12151 A1	02/22/2001	Clayton		
	109	WO	01/13865 A1	03/01/2001	Murad		
	110	WO	01/83031 A1	11/08/2001	Bioderm		
	111	WO	02/69910 A2	09/12/2002	Beiersdorf		Abstract
	112	WO	02/76470 A1	10/03/2002	Kanebo Ltd.		Abstract
	113	WO	02/98253 A1	12/12/2002	Puma Aktiengesellschaft		Abstract

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS

EXAMINER INITIALS*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ⁶
	114	Oikarinen, A., "The Aging of Skin: Chronoaging Versus Photoaging", Photodermatol. Photoimmunol. Photomed., Vol. 7, pp. 3-4, (1990)	

EXAMINER

DATE CONSIDERED